Share

Low Risk Thyroid Cancer: Rating the Risks

ENDO_2022_4C While certain thyroid cancer patients who have very small nodules well-located within the thyroid can be counseled rather than operated on, other patients might fare better undergoing surgery. At ENDO 2022, experts weigh in and debate when to operate and when to watch in patients with low-risk thyroid cancer in the session “Endocrine Debate: Low...
Share

New Report Highlights Reveal Future of Insulin Biosimilars

Last summer, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. The FDA granted approval for insulin glargine-yfgn to Mylan Pharmaceuticals Inc., who is marketing the product as Semglee. Semglee...
Share

Care Package: Christine M. Burt Solorzano, MD, Discusses the Endocrine Society’s Newly Expanded Patient Engagement

Burt SolorzanoC Endocrine News talks with Christine M. Burt Solorzano, MD, chair of the committee that helped launch the Endocrine Society’s reinvigorated patient outreach program, EndoCares. With an in-person event taking place in Atlanta during ENDO 2022, EndoCares is set to become an important bridge between the Endocrine Society’s members and the patients they treat.   The...
Share

All About Adrenal: Analyzing Two Years of Research

ENDO_2022_4C When the ENDO 2022 session “Clinical Year in Review: All Things Adrenal” gets underway, Gary Hammer, MD, PhD, will treat attendees to the series of advances that have been made in adrenal science and clinical practice over the last two years, from adrenal homeostasis, glucocorticoid biology, and adrenal insufficiency to Cushing’s, tumors, pheochromocytoma, and more....
Share

Gender-Affirming Care: Bridging the Gap

ENDO_2022_4C As transgender medical care becomes unfairly politicized, presentations such as ENDO 2022’s Meet the Professor session “Beginner’s Guide to Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults” are more essential than ever. Attendees will be shown a variety of best practices in providing affirming care to transgender and gender diverse adults.   On the...
Share

Phase III LINC 4 Study Confirms Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease

Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety...
Show More